Clinical trial
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for…
NCT00004376 · National Center for Research Resources (NCRR), NIH · Completed
Key facts
| NCT number | NCT00004376 |
|---|---|
| Title | Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder |
| Lead sponsor | National Center for Research Resources (NCRR), NIH |
| Collaborators | Yale University |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tourette Syndrome |
| Intervention type | Drug |
| Interventions | guanfacine |
| Enrollment | 35 |
| Start date | Sep 1, 1994 |
| Completion | Jun 1, 2000 |
| First posted | Oct 19, 1999 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: